Advertisement

Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity

      Abstract

      Familial combined hyperlipidemia (FCHL) is characterized by elevated levels of serum total cholesterol (TC), triglyceride (TG), or both. The increased incidence of coronary artery diseases (CAD) in the patients with FCHL is believed to be caused by circulating atherogenic lipoproteins associated with the complex phenotype. Recent establishment of sensitive detection system for malondialdehyde-modified (MDA)-LDL, which is one of oxidized lipoproteins, showed its increased circulating level in the patients with CAD. In order to know the atherogenic lipoproteins resulted from the dyslipidemia observed in FCHL, we measured the serum MDA-LDL level in the patients. The circulating MDA-LDL level and the ratio of MDA-LDL and LDL-C in FCHL were significantly higher (P<0.05) than those in control, which are adjusted about the age, serum TC, LDL-C and HDL-C levels, respectively. Furthermore, the circulating MDA-LDL level and the ratio of MDA-LDL and LDL-C were negatively correlated (R=−0.635, P<0.01 and R=−0.702, P<0.01, respectively) with hepatic lipase (HL) activity in FCHL. The serum MDA-LDL level and the ratio of MDA-LDL and LDL-C were in the subjects with T/T genotypes in the HL C-514T polymorphism were significantly increased compared to those with C/C genotype, respectively. The subjects with T/T genotype showed the activities to 65 and 79% of those in the subjects with C/C genotype in male and female, respectively. The intima-media thickness (IMT) of carotid artery was significantly higher (P<0.05) in the subjects with T/T genotype than those with C/C genotype in male. These findings indicate that the circulating MDA-LDL level is possibly contributing the atherogenic process in FCHL, and the common HL polymorphism might be a determinant of the serum level of oxidized LDL in the patients with FCHL.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldstein J.L
        • Schrott H.G
        • Hazzard W.R
        • Bierman E.L
        • Motulsky A.G
        Hyperlipidemia in coronary heart disease. Part II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.
        J. Clin. Invest. 1973; 52: 1544-1568
        • Rose H.G
        • Kranz P
        • Weinstock M
        • Juliano J
        • Haft J.I
        Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype.
        Am. J. Med. 1973; 54: 148-160
        • Nikkila E.A
        • Aro A
        Family study of serum lipids and lipoproteins in coronary heart-disease.
        Lancet. 1973; 1: 954-959
        • Kotani K
        • Maekawa M
        • Kanno T
        • Kondo A
        • Toda N
        • Manabe M
        Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.
        Biochim. Biophys. Acta. 1994; 1215: 121-125
        • Itabe H
        • Yamamoto H
        • Imanaka T
        • Shimamura K
        • Uchiyama H
        • Kimura J
        • et al.
        Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody.
        J. Lipid Res. 1996; 37: 45-53
        • Palinski W
        • Horkko S
        • Miller E
        • Steinbrecher U.P
        • Powell H.C
        • Curtiss L.K
        • et al.
        Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.
        J. Clin. Invest. 1996; 98: 800-814
        • Holvoet P
        • Stassen J.M
        • Van Cleemput J
        • Collen D
        • Vanhaecke J
        Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 100-107
        • Toshima S
        • Hasegawa A
        • Kurabayashi M
        • Itabe H
        • Takano T
        • Sugano J
        • et al.
        Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2243-2247
        • Holvoet P
        • Mertens A
        • Verhamme P
        • Bogaerts K
        • Beyens G
        • Verhaeghe R
        • et al.
        Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 844-848
        • Ehara S
        • Ueda M
        • Naruko T
        • Haze K
        • Itoh A
        • Otsuka M
        • et al.
        Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
        Circulation. 2001; 103: 1955-1960
        • Kondo A
        • Muranaka Y
        • Ohta I
        • Notsu K
        • Manabe M
        • Kotani K
        • et al.
        Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL.
        Clin. Chem. 2001; 47: 893-900
        • Tanaga K
        • Bujo H
        • Inoue M
        • Mikami K
        • Kotani K
        • Takahashi K
        • et al.
        Incteased circulating MDA-LDL levels in patients with coronary artery diseases and its association with the peak sizes of LDL particles.
        Arterioscler. Thromb. Vasc. Biol. 2002; 22: 662-666
        • Cohen J.C
        • Vega G.L
        • Grundy S.M
        Hepatic lipase: new insights from genetic and metabolic studies.
        Curr. Opin. Lipidol. 1999; 10: 259-267
        • Zambon A
        • Deeb S.S
        • Hokanson J.E
        • Brown B.G
        • Brunzell J.D
        Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1723-1729
        • Nie L
        • Wang J
        • Clark L.T
        • Tang A
        • Vega G.L
        • Grundy S.M
        • et al.
        Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity.
        J. Lipid Res. 1998; 39: 1127-1130
        • Couture P
        • Otvos J.D
        • Cupples L.A
        • Lahoz C
        • Wilson P.W
        • Schaefer E.J
        • et al.
        Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: the Framingham Offspring Study.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 815-822
        • Jansen H
        • Chu G
        • Ehnholm C
        • Dallongeville J
        • Nicaud V
        • Talmud P.J
        The T allele of the hepatic lipase promoter variant C-480T is associated with increased fasting lipids and HDL and increased preprandial and postprandial LpCIII:B: European Atherosclerosis Research Study (EARS) II.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 303-308
        • Carr M.C
        • Hokanson J.E
        • Deeb S.S
        • Purnell J.Q
        • Mitchell E.S
        • Brunzell J.D
        A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 2701-2707
        • Guerra R
        • Wang J
        • Grundy S.M
        • Cohen J.C
        A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol.
        Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 4532-4537
        • Vega G.L
        • Clark L.T
        • Tang A
        • Marcovina S
        • Grundy S.M
        • Cohen J.C
        Hepatic lipase activity is lower in African American men than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC).
        J. Lipid Res. 1998; 39: 228-232
        • Taira K
        • Bujo H
        • Kobayashi J
        • Takahashi K
        • Miyazaki A
        • Saito Y
        Positive family history for CHD and “midband lipoproteins” are potential risk factors of carotid atherosclerosis in familial hypercholesterolemia.
        Atherosclerosis. 2002; 160: 391-397
        • Friedewald W.T
        • Levy R.I
        • Fredrickson D
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499-502
        • Zhu Y
        • Bujo H
        • Takahashi K
        • Taira K
        • Kobayashi J
        • Koshikawa H
        • et al.
        Severe hypertriglyceridemia with plasma inhibitory factor(s) on lipoprotein lipase activity in a patient with a common Ser(447)-Ter LPL mutation.
        Clin. Chim. Acta. 2001; 308: 139-146
        • Steinberg D
        Role of oxidized LDL and antioxidants in atherosclerosis.
        Adv. Exp. Med. Biol. 1995; 369: 39-48
        • Witztum J.L
        Immunological response to oxidized LDL.
        Atherosclerosis. 1997; 131: 9-11
        • Jessup W
        • Kritharides L
        Metabolism of oxidized LDL by macrophages.
        Curr. Opin. Lipidol. 2000; 11: 473-481
        • Dugi K.A
        • Brandauer K
        • Schmidt N
        • Nau B
        • Schneider J.G
        • Mentz S
        • et al.
        Low hepatic lipase activity is a novel risk factor for coronary artery disease.
        Circulation. 2001; 104: 3057-3062
        • Zambon A
        • Deeb S.S
        • Brown B.G
        • Hokanson J.E
        • Brunzell J.D
        Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
        Circulation. 2001; 103: 792-798
        • Pihlajamaki J
        • Karjalainen L
        • Karhapaa P
        • Vauhkonen I
        • Taskinen M.R
        • Deeb S.S
        • et al.
        G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1789-1795
        • Carr M.C
        • Hokanson J.E
        • Zambon A
        • Deeb S.S
        • Barrett P.H
        • Purnell J.Q
        • et al.
        The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity.
        J. Clin. Endocrinol. Metab. 2001; 86: 2831-2837